How Long Does MAT Treatment Last?

It is one of the first questions people ask before starting medication-assisted treatment — and one of the most important to answer honestly.

The honest answer: MAT duration is clinically determined, individually variable, and often longer than most people expect. And that is not a problem. It is the point.

‍

There Is No Standard Duration — and That Is by Design

SAMHSA and the American Society of Addiction Medicine (ASAM) do not specify a fixed endpoint for MAT. Both organizations recommend that treatment continue for as long as it is clinically beneficial — a standard that, for many people with opioid use disorder, means one year at minimum and often several years or more.

Addiction is a chronic condition. MAT treats it the way we treat other chronic conditions — with sustained, clinically monitored medication rather than a time-limited intervention.

Setting an arbitrary endpoint is not evidence-based practice. It is the most common point at which preventable relapse occurs.

‍

Duration by Medication Type

‍

‍

What Determines How Long You Stay on MAT?

Your clinical team at Bold Recovery reviews your MAT status regularly. The factors that influence duration include:

‍

Craving intensity and frequency

As long as clinically significant cravings are present, MAT is providing active clinical benefit. Tapering before cravings resolve substantially increases relapse risk.

‍

Life and environmental stability

Housing security, employment, relationships, and social supports all affect when tapering is clinically appropriate. MAT supports stability while those foundations are built. Tapering during instability increases vulnerability unnecessarily.

‍

Co-occurring mental health conditions

Depression, anxiety, PTSD, and trauma commonly co-occur with opioid use disorder. When these conditions are active, extended MAT duration is typically indicated — the neurobiological stabilization that MAT provides is directly relevant to mental health symptom management.

‍

History of relapse

Prior relapses after treatment—especially after previous MAT discontinuation—are among the strongest clinical indicators for longer duration. Each relapse event, particularly opioid relapse after a period of abstinence, carries acute overdose risk due to reduced tolerance.

‍

When Is Tapering Appropriate?

Tapering — the gradual reduction of MAT medication — is a clinical process, not a milestone you reach on a calendar. At Bold Recovery, tapering discussions begin when:

• Cravings have been consistently low or absent for a sustained period
• Your home environment, employment, and relationships are stable
• You have robust behavioral coping skills and a strong recovery support network
• You and your clinical team agree the timing is right—not because of external pressure or arbitrary timelines

‍

Tapering is always done gradually under clinical supervision. Abrupt discontinuation carries significant risk and is never recommended.

‍

The Risk of Stopping MAT Too Early

This is the piece most people do not hear clearly enough: stopping MAT before clinical readiness dramatically increases overdose mortality risk. Tolerance drops rapidly after buprenorphine or methadone discontinuation. If relapse occurs — even to a previously manageable dose — the physiological response can be fatal.

The research is unambiguous. Longer MAT duration is associated with lower overdose mortality, lower relapse rates, and higher rates of sustained recovery. There is no clinical benefit to stopping sooner than your recovery trajectory supports.

‍